"We are honored to be working with Ms. Dayana Mendoza, the Latino Commission on AIDS, and so many dedicated state and local organizations to raise awareness of the importance of HIV testing on National Latino AIDS Awareness Day," said Douglas A. Michels, President and Chief Executive Officer of OraSure Technologies. "Now for the first time ever, individuals have access to the OraQuick In-Home HIV test – the same test healthcare professionals have used and trusted for years – that will empower them to learn their HIV status in the comfort and privacy of their own homes."

Despite testing options that have been available for years, the Centers for Disease Control and Prevention (CDC) estimate that approximately 1.2 million people in the U.S. have HIV and approximately 240,000 of them are unaware of their status. Those who do not know they are HIV positive are disproportionately responsible for a majority of the 50,000 new HIV infections that occur each year. The CDC recommends routine HIV screening for all people ages 13 to 64, with more frequent testing for people at higher risk.

The OraQuick® In-Home HIV Test detects antibodies to both HIV-1 and HIV-2 with an oral swab, providing a confidential in-home testing option with results in as little as 20 minutes. The in-home test is an over-the-counter version of OraQuick ADVANCE ®, an oral swab rapid test with more than 25 million units sold in the professional market, including doctors, hospitals, clinics and other trained professionals. The OraQuick In-Home HIV Test is now available in retail stores nationwide, through select retailers online and at OraQuick.com.

NLAAD Press Conference Information:

In recognition of National Latino AIDS Awareness Day, The Latino Commission on AIDS will hold a press conference on Monday, October 15 th at 10:00 AM on the steps of New York City Hall.  

About OraSure Technologies

OraSure Technologies is a leader in the development, manufacture and distribution of oral fluid diagnostic and collection devices and other technologies designed to detect or diagnose critical medical conditions. Its innovative products include rapid tests for the detection of antibodies to HIV and HCV at the point of care and testing solutions for detecting various drugs of abuse. In July 2012, the Company received approval from the U.S. Food and Drug Administration for the Company's OraQuick® In-Home HIV Test for sale directly to consumers in the over-the-counter (OTC) market – making it the first and only rapid OTC HIV test approved in the U.S. In addition, the Company is a leading provider of oral fluid sample collection, stabilization and preparation products for molecular diagnostic applications. OraSure's portfolio of products is sold globally to various clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, research and academic institutions, distributors, government agencies, physicians' offices, and commercial and industrial entities. The Company's products enable healthcare providers to deliver critical information to patients, empowering them to make decisions to improve and protect their health. 

If you liked this article you might like

Stocks Under $10 Portfolio: Not Resting on Our Laurels

How to Cash in on the Fight Against the Zika Virus

OraSure (OSUR) Stock Spikes, Upgraded at Stephens

4 Stocks for Fighting Zika

OraSure Technologies (OSUR) Stock Jumps on Zika Test Contract